Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
TILADE is an inhaled solution small-molecule drug approved in 1997 for chronic respiratory disease management. The exact indication and mechanism of action are not specified in available data, but the inhalation route suggests pulmonary delivery for a maintenance or symptom-relief indication. This is a legacy NDA product currently approaching loss of exclusivity.
Product is in late-stage maturity with LOE approaching; commercial team focus is likely on defensive pricing and generic transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TILADE offers limited career advancement opportunities due to its LOE-approaching status and zero linked job openings. Roles available are primarily defensive and focused on managed decline rather than growth, making this a transitional or holding position for professionals expecting portfolio changes at Sanofi.
Worked on TILADE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.